Floatz logo

31 assets in B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)

Therapeutic assets addressing B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2), rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Nilotinib
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
The University of Hong KongP2BBB (74)
Blinatumomab
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
Novartis PharmaceuticalsP3BBB (72)
Cytarabine
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
Novartis PharmaceuticalsP3BBB (72)
Imatinib
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
The University of Hong KongP3BB (69)
Dasatinib
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
SWOG Cancer Research NetworkP3BB (67)
Methotrexate
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
Novartis PharmaceuticalsP3BB (66)
Olverembatinib
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
Institute of Hematology & Blood Diseases Hospital, ChinaP3BB (66)
Ponatinib
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
University of AlbertaP3BB (65)
Prednisone
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
University of WashingtonP3BB (65)
(+)-Vincristine
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
Novartis PharmaceuticalsP2BB (65)
Cyclophosphamide
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
SWOG Cancer Research NetworkP3BB (64)
Dexasone
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
Novartis PharmaceuticalsP3BB (64)
Flumatinib
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
The First Affiliated Hospital of Soochow UniversityP3BB (64)
Venetoclax
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
Institute of Hematology & Blood Diseases Hospital, ChinaP2BB (64)
Etoposide
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
SWOG Cancer Research NetworkP3B (63)
Mercaptopurine Anhydrous
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
PETHEMA FoundationP3B (63)
Nivestim
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
University of WashingtonP2B (63)
Pegaspargase
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
Children's Oncology GroupP3B (63)
Adriamycin
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
SWOG Cancer Research NetworkP3B (62)
Asciminib
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
Novartis PharmaceuticalsP2B (62)
Hydrocortisone
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
Novartis PharmaceuticalsP3B (62)
Rituximab
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
SWOG Cancer Research NetworkP2B (60)
Azacitidine
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
The First Affiliated Hospital of Soochow UniversityP2B (57)
Calaspargase Pegol
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
Children's Oncology GroupP3B (57)
Pegfilgrastim
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
University of WashingtonP2CCC (53)
Tucidinostat
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
Nanfang Hospital, Southern Medical UniversityP2CCC (53)
Prednisolone
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
Novartis PharmaceuticalsP1/2CC (45)
19-28z/il-18 car t cells
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
Memorial Sloan Kettering Cancer CenterP1CC (43)
Egfrt/19-28Z/Il-12 Car T-Lymphocytes
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
Memorial Sloan Kettering Cancer CenterP1CC (43)
lp-118
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
Wake Forest University Health SciencesP1CC (43)